These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 38414738)
1. Exploring the efficacy and safety of Ambroxol in Gaucher disease: an overview of clinical studies. Mohamed FE; Al-Jasmi F Front Pharmacol; 2024; 15():1335058. PubMed ID: 38414738 [TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116 [TBL] [Abstract][Full Text] [Related]
12. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease. Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. Kim YM; Yum MS; Heo SH; Kim T; Jin HK; Bae JS; Seo GH; Oh A; Yoon HM; Lim HT; Kim HW; Ko TS; Lim HS; Osborn MJ; Tolar J; Cozma C; Rolfs A; Zimran A; Lee BH; Yoo HW J Med Genet; 2020 Feb; 57(2):124-131. PubMed ID: 31649052 [TBL] [Abstract][Full Text] [Related]
14. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease. Jiang W; Yi M; Maegawa GHB; Zhang H J Hum Genet; 2020 Mar; 65(3):345-349. PubMed ID: 31822786 [TBL] [Abstract][Full Text] [Related]
15. A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin. Kinghorn KJ; Grönke S; Castillo-Quan JI; Woodling NS; Li L; Sirka E; Gegg M; Mills K; Hardy J; Bjedov I; Partridge L J Neurosci; 2016 Nov; 36(46):11654-11670. PubMed ID: 27852774 [TBL] [Abstract][Full Text] [Related]
16. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179 [TBL] [Abstract][Full Text] [Related]
17. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data. Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887 [TBL] [Abstract][Full Text] [Related]
18. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Menozzi E; Toffoli M; Schapira AHV Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432 [TBL] [Abstract][Full Text] [Related]
19. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808 [TBL] [Abstract][Full Text] [Related]
20. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy. Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]